Antibiotic management of lung infections in cystic fibrosis: II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi

Annals of the American Thoracic Society

Volumn 11, Issue 8, 2014, Pages 1298-1306

  Chmiel, James F ^a   Aksamit, Timothy R ^b   Chotirmall, Sanjay H ^c,d   Dasenbrook, Elliott C ^e   Stuart Elborn, J ^f   LiPuma, John J ^g   Ranganathan, Sarath C ^h   Waters, Valerie J ⁱ   Ratjen, Felix A ⁱ  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c BEAUMONT HOSPITAL   (Ireland)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Anaerobic bacteria; Aspergillus fumigatus; Mycobacterium abscessus; Mycobacterium avium complex; Scedosporium species complex

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOXITIN; CLARITHROMYCIN; IMIPENEM; ITRACONAZOLE; LINEZOLID; MACROLIDE; TIGECYCLINE; VORICONAZOLE; ANTIINFECTIVE AGENT;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIAL COLONIZATION; BACTERIUM DETECTION; CANDIDA; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; FUNGAL COLONIZATION; HUMAN; LUNG INFECTION; LUNG MYCOSIS; MICROBIOLOGY; MIXED INFECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SCEDOSPORIUM; SPUTUM ANALYSIS; COMPLICATION; FUNGUS; ISOLATION AND PURIFICATION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RESPIRATORY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; CYSTIC FIBROSIS; FUNGI; HUMANS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RESPIRATORY TRACT INFECTIONS;

EID: 84912080439     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201405-203AS     Document Type: Article

References (86)

1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-482.
2. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003;4:8.
3. Courtney JM, Dunbar KE, McDowell A, Moore JE, Warke TJ, Stevenson M, Elborn JS. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004;3:93-98.
4. 1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178:814-821.
5. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-1049.
6. 1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J 2014;43:125-133.
7. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LipPuma JJ, Ranganathan SC, Waters V, Ratjen F. Antibiotic management of lung infections in cystic fibrosis: the microbiome, MRSA, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 2014;11:1120-1129.
8. Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013;34:87-94.
9. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Diseases Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416. [Published erratum appears in Am J Respir Crit Care Med 175:744-745.]
10. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, et al.; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828-834.
11. Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, Bellis G, Vibet MA, Le Roux E, Lemonnier L, et al.; Jean-Louis Herrmann for the OMA Group. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009;47:4124-4128.
12. Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010;9:117-123.
13. Chalermskulrat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP, Paradowski LJ, Aris RM. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006;61:507-513.
14. Falkinham JO III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011;17:419-424.
15. Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, Pace NR. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci USA 2009;106:16393-16399.
16. Nishiuchi Y, Maekura R, Kitada S, Tamaru A, Taguri T, Kira Y, Hiraga T, Hirotani A, Yoshimura K, Miki M, et al. The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis 2007;45:347-351.
17. De Groote MA, Pace NR, Fulton K, Falkinham JO III. Relationships between Mycobacterium isolates from patients with pulmonary mycobacterial infection and potting soils. Appl Environ Microbiol 2006;72:7602-7606.
18. Falkinham JO III. Reducing human exposure to Mycobacterium avium. Ann Am Thorac Soc 2013;10:378-382.
19. Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, Brown MR, Chernick M, Steagall WK, Glasgow CG, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178:1066-1074.
20. Saiman L, Siegel J; Cystic Fibrosis Foundation. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24(5, Suppl):S6-S52.
21. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012;185:231-232.
22. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013;381:1551-1560.
23. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309:1251-1259.
24. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, Emmett P, Marshall B, Accurso F, Sagel S, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012;142:1259-1266.
25. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309:1260-1267.
26. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2012 [accessed September 2014];11:CD002203. Available from: http://summaries.cochrane.org/
27. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-667.
28. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-689.
29. Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013;188:807-812.
30. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007;7:2.
31. Colin AA, Ali-Dinar T. Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up. Pediatr Pulmonol 2010;45:626-627.
32. Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013;34:124-134.
33. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009;53:1367-1376.
34. Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, Lee K, Lee SH, Daley CL, Kim S, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012;186:917-925.
35. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.
36. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012;15:149-161.
37. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-325.
38. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, Sarles J, Raoult D, Rolain JM. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008;3:e2908.
39. Brook I, Fink R. Transtracheal aspiration in pulmonary infection in children with cystic fibrosis. Eur J Respir Dis 1983;64:51-57.
40. Jewes LA, Spencer RC. The incidence of anaerobes in the sputum of patients with cystic fibrosis. J Med Microbiol 1990;31:271-274.
41. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984;104:352-356.
42. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, et al.Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:995-1001.
43. Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N, Borneff-Lipp M, Döring G. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009;15:454-460.
44. Lambiase A, Catania MR, Rossano F. Anaerobic bacteria infection in cystic fibrosis airway disease. New Microbiol 2010;33:185-194.
45. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, Connett GJ, Bruce KD. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 2006;44:2601-2604.
46. Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T, Brennan S, Ranganathan S, Robins-Browne R, Sly PD; AREST CF. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011;53:425-432.
47. Tai A, Ranganath S. Anaerobic bacterial infection in patients with cystic fibrosis. Am J Respir Crit Care Med 2008;178:994.
48. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008;105:15070-15075.
49. Ulrich M, Beer I, Braitmaier P, Dierkes M, Kummer F, Krismer B, Schumacher U, Gräpler-Mainka U, Riethmüller J, Jensen PO, et al. Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 2010;65:978-984.
50. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011;66:579-584.
51. Delhaes L, Monchy S, Fré alle E, Hubans C, Salleron J, Leroy S, Prevotat A, Wallet F, Wallaert B, Dei-Cas E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community - Implications for therapeutic management. PLoS One 2012;7:e36313.
52. Haase G, Skopnik H, Kusenbach G. Exophiala dermatitidis infection in cystic fibrosis. Lancet 1990;336:188-189.
53. Haase G, Skopnik H, Groten T, Kusenbach G, Posselt HG. Long-term fungal cultures from sputum of patients with cystic fibrosis. Mycoses 1991;34:373-376.
54. Horré R, Schaal KP, Siekmeier R, Sterzik B, de Hoog GS, Schnitzler N. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis: a prospective study. Respiration 2004;71:360-366.
55. Kusenbach G, Skopnik H, Haase G, Friedrichs F, Döhmen H. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 1992;151:344-346.
56. Blaschke-Hellmessen R, Lauterbach I, Paul KD, Tintelnot K, Weissbach G. [Detection of Exophiala dermatitidis (Kano) De Hoog 1977 in septicemia of a child with acute lymphatic leukemia and in patients with cystic fibrosis]. Mycoses 1994;37:89-96.
57. Kondori N, Gilljam M, Lindblad A, Jönsson B, Moore ER, Wenneras C. High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency. J Clin Microbiol 2011;49:1004-1009.
58. Giraud S, Favennec L, Bougnoux ME, Bouchara JP. Rasamsonia argillacea species complex: taxonomy, pathogenesis and clinical relevance. Future Microbiol 2013;8:967-978.
59. Chotirmall SH, Al-Alawi M, Mirkovic B, Lavelle G, Logan PM, Greene CM, McElvaney NG. Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int 2013;2013:723129.
60. Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens? Int J Biochem Cell Biol 2014;52:161-173.
61. 1 decline and hospital-treated exacerbations in cystic fibrosis. Chest 2010;138:1186-1195.
62. Chotirmall SH, Greene CM, McElvaney NG. Candida species in cystic fibrosis: a road less travelled. Med Mycol 2010;48:S114-S124.
63. Chotirmall SH, Branagan P, Gunaratnam C, McElvaney NG. Aspergillus/allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity. Respir Care 2008;53:1035-1041.
64. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, et al.; Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis - State of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37:S225-S264.
65. Gernez Y, Dunn CE, Everson C, Mitsunaga E, Gudiputi L, Krasinska K, Davies ZA, Herzenberg LA, Tirouvanziam R, Moss RB. Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by Aspergillus allergens. J Cyst Fibros 2012;11:502-510.
66. Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros 2009;8:253-257.
67. Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2012 [accessed September 2014];6:CD002204. Available from: http://summaries.cochrane.org/
68. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, Honoré I, Dupouy-Camet J, Dusser D, Klaassen CH, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012;56:869-874.
69. Rondeau S, Couderc L, Dominique S, Pramil S, Leguillon C, Masseline B, Favennec L, Marguet C. High frequency of voriconazole-related phototoxicity in cystic fibrosis patients. Eur Respir J 2012;39:782-784.
70. Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014;49:503-507.
71. Fillaux J, Brémont F, Murris M, Cassaing S, Rittié JL, Tétu L, Segonds C, Abbal M, Bieth E, Berry A, et al. Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients. Scand J Infect Dis 2012;44:842-847.
72. Baxter CG, Moore CB, Jones AM, Webb AK, Denning DW. IgEmediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest 2013;143:1351-1357.
73. Fillaux J, Brémont F, Murris M, Cassaing S, Tétu L, Segonds C, Pipy B, Magnaval JF. Aspergillus sensitization or carriage in cystic fibrosis patients. Pediatr Infect Dis J 2014;33:680-686.
74. Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013;132:560-566.e510.
75. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010;137:171-176.
76. McMahon MA, Chotirmall SH, McCullagh B, Branagan P, McElvaney NG, Logan PM. Radiological abnormalities associated with Aspergillus colonization in a cystic fibrosis population. Eur J Radiol 2012;81:e197-e202.
77. Coughlan CA, Chotirmall SH, Renwick J, Hassan T, Low TB, Bergsson G, Eshwika A, Bennett K, Dunne K, Greene CM, et al. The effect of Aspergillus fumigatus infection on vitamin D receptor expression in cystic fibrosis. Am J Respir Crit Care Med 2012;186:999-1007.
78. Aaron SD, Vandemheen KL, Freitag A, Pedder L, Cameron W, Lavoie A, Paterson N, Wilcox P, Rabin H, Tullis E, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012;7:e36077.
79. Hassan T, Chotirmall SH, Low TB, Flynn MG, McElvaney NG, Gunaratnam C. Thrombolysis for indwelling catheter related thrombosis and superior vena cava obstruction in cystic fibrosis: a case series. Ir J Med Sci 2010;179:469-470.
80. Cimon B, Carrére J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000;19:53-56.
81. Williamson EC, Speers D, Arthur IH, Harnett G, Ryan G, Inglis TJ. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplification of ribosomal intergenic spacer sequences in patients with chronic lung disease. J Clin Microbiol 2001;39:47-50.
82. Tintelnot K, Just-Nübling G, Horré R, Graf B, Sobottka I, Seibold M, Haas A, Kaben U, De Hoog GS. A review of German Scedosporium prolificans cases from 1993 to 2007. Med Mycol 2009;47:351-358.
83. Summerbell RC, Krajden S, Kane J. Potted plants in hospitals as reservoirs of pathogenic fungi. Mycopathologia 1989;106:13-22.
84. Blyth CC, Middleton PG, Harun A, Sorrell TC, Meyer W, Chen SC. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol 2010;48:S37-S44.
85. Defontaine A, Zouhair R, Cimon B, Carrére J, Bailly E, Symoens F, Diouri M, Hallet JN, Bouchara JP. Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol 2002;40:2108-2114.
86. Guarro J, Kantarcioglu AS, Horré R, Rodriguez-Tudela JL, Cuenca Estrella M, Berenguer J, de Hoog GS. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 2006;44:295-327.